2014
DOI: 10.1586/1744666x.2014.920234
|View full text |Cite
|
Sign up to set email alerts
|

Risk for complications in patients with hemophagocytic lymphohistiocytosis who undergo hematopoietic stem cell transplantation: myeloablative versus reduced-intensity conditioning regimens

Abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option for patients with primary hemophagocytic lymphohistiocytosis (HLH) and for patients with secondary HLH who fail to respond to therapy. Advances in HSCT and supportive care measures have resulted in improved patient outcomes and decreased treatment-related mortality. Despite the overall improvement in outcome, HLH patients who undergo HSCT using myeloablative conditioning regimens are still at significant risk for complication… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 38 publications
0
4
0
Order By: Relevance
“…Debates about best preparative regimens are ongoing without resolution. Recently, the use of reduced‐intensity conditioning (RIC) regimens has shown favorable outcomes and lower rate of acute complications when compared to conventional HSCT 2 . A prospective national RIC HCT trial for HLH/primary immunodeficiency resulted in low early mortality and 1‐year overall survival (OS) of 80% (HLH only disease 82%), but 66.7% 18‐month OS (HLH only disease 68%) 1 .…”
Section: Literature (Patient#) Marsh Et Al 20137(79) Allen Et Al 2018mentioning
confidence: 99%
“…Debates about best preparative regimens are ongoing without resolution. Recently, the use of reduced‐intensity conditioning (RIC) regimens has shown favorable outcomes and lower rate of acute complications when compared to conventional HSCT 2 . A prospective national RIC HCT trial for HLH/primary immunodeficiency resulted in low early mortality and 1‐year overall survival (OS) of 80% (HLH only disease 82%), but 66.7% 18‐month OS (HLH only disease 68%) 1 .…”
Section: Literature (Patient#) Marsh Et Al 20137(79) Allen Et Al 2018mentioning
confidence: 99%
“…Although more than 7500 children receive this treatment annually in the United States and Europe, the success of this therapy is limited by a broad range of post-HCT pulmonary injuries that develop in 10 to 40% of pediatric recipients in response to chemotherapeutic toxicity, infection, and impaired or dysregulated immunity (1)(2)(3). Comprehensive assessment of pulmonary health before HCT conditioning is critical to identify high-risk patients who may benefit from modified conditioning chemotherapy regimens, closer surveillance, and risk-stratified treatments aimed at mitigating the development of irreversible pulmonary toxicity (4)(5)(6).…”
Section: Introductionmentioning
confidence: 99%
“…While more than 7,500 children receive this treatment annually in the United States and Europe, the success of this therapy is limited by a broad range of post-HCT pulmonary injuries that develop in 10-40% of pediatric recipients in response to chemotherapeutic toxicity, infection, and impaired or dysregulated immunity (1)(2)(3). Comprehensive assessment of pulmonary health prior to HCT conditioning is critical in order to identify high-risk patients who may benefit from modified conditioning chemotherapy regimens, closer surveillance, and risk-stratified treatments aimed at mitigating the development of irreversible pulmonary toxicity (4)(5)(6).…”
Section: Introductionmentioning
confidence: 99%